# Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer

> **NCT03984214** · PHASE3 · COMPLETED · sponsor: **Arbeitsgemeinschaft medikamentoese Tumortherapie** · enrollment: 109 (actual)

## Conditions studied

- Pancreatic Cancer Non-resectable
- Chemotherapy-induced Nausea and Vomiting
- Pancreatic Cancer Metastatic

## Interventions

- **DRUG:** Dronabinol in Oral Dosage Form
- **DRUG:** Placebo in Oral Dosage Form

## Key facts

- **NCT ID:** NCT03984214
- **Lead sponsor:** Arbeitsgemeinschaft medikamentoese Tumortherapie
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-16
- **Primary completion:** 2024-09-25
- **Final completion:** 2024-09-25
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2025-04-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03984214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03984214, "Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03984214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*